Aurobindo Pharma Ltd (AUROPHARMA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aurobindo Pharma Ltd (AUROPHARMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013142
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceutical company which develops, manufactures and exports formulations and active pharmaceutical ingredients (API’s). Its products portfolio include active pharma ingredients, formulations, antibiotics, anti-retrovirals, anti- allergics, gastroenterologicals, anti-Diabetics, HIVs, peptides, nutraceutical and aurozymes. It also offers contract research and manufacturing services across all the clinical stages of drug lifecycle. Aurobindo Pharma conducts research and development in the areas of product identification, literature evaluation, API process development, formulation development, pilot BA or BE, exhibiting batches for dossier submission, stability studies for global requirements, and dossier submission. The company has presence in China, South Africa, Australia, Germany, Japan, the US, the UK, and others. Aurobindo pharma is headquartered in Hyderabad, Telangana, India.

Aurobindo Pharma Ltd (AUROPHARMA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 13
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 14
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 15
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 16
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 18
Partnerships 20
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 20
Celon Labs Forms Joint Venture with Aurobindo Pharma 21
Aurobindo Pharma Forms Joint Venture With DIODE 22
Licensing Agreements 23
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 23
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 25
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 26
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 27
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 28
Equity Offering 30
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 30
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 31
Asset Transactions 32
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 32
Acquisition 33
Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 33
Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 34
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 35
Aurobindo Pharma Acquires Natrol for USD132.5 Million 36
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 37
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 38
Aurobindo Pharma To Acquire Branded Formulations Marketing Company 39
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 40
Aurbindo Pharma Sells 50% Stake In Cephazone Pharma, Maker Of Cephalosporin Products 41
Aurobindo Pharma Ltd – Key Competitors 42
Aurobindo Pharma Ltd – Key Employees 43
Aurobindo Pharma Ltd – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 47
Recent Developments 48
Financial Announcements 48
Nov 09, 2017: Aurobindo Pharma: Q2 FY17-18 Financial Results 48
Aug 09, 2017: Aurobindo Pharma: Consolidated Financial & Business Highlights – Q1FY18 50
Feb 09, 2017: Aurobindo Pharma Announces Q3 results & Limited Review Report for the Quarter ended December 31, 2016 51
Aug 23, 2016: Aurobindo Pharma Announces Results for the Quarter Ended June 30, 2016 52
May 30, 2016: Aurobindo Pharma: Q4 FY15-16 and FY15-16 Financial Results 53
Feb 09, 2016: Aurobindo Pharma Announces results for the quarter ended December 31, 2015 54
Corporate Communications 55
Feb 09, 2017: Aurobindo Pharma Announces Change in Board of Directors 55
Legal and Regulatory 56
Apr 19, 2017: Aurobindo Pharma Provides Update on US FDA Inspection at Bachupally Manufacturing Facility 56
Product News 57
04/26/2016: Aurobindo Pharma receives USFDA Approval for Amlodipine and Valsartan Tablets 57
03/30/2017: Aurobindo Pharma receives USFDA Approval for Generic Epzicom tablets 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aurobindo Pharma Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 13
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 14
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 15
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 16
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 18
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 20
Celon Labs Forms Joint Venture with Aurobindo Pharma 21
Aurobindo Pharma Forms Joint Venture With DIODE 22
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 23
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 25
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 26
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 27
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 28
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 30
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 31
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 32
Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 33
Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 34
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 35
Aurobindo Pharma Acquires Natrol for USD132.5 Million 36
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 37
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 38
Aurobindo Pharma To Acquire Branded Formulations Marketing Company 39
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 40
Aurbindo Pharma Sells 50% Stake In Cephazone Pharma, Maker Of Cephalosporin Products 41
Aurobindo Pharma Ltd, Key Competitors 42
Aurobindo Pharma Ltd, Key Employees 43
Aurobindo Pharma Ltd, Other Locations 44
Aurobindo Pharma Ltd, Subsidiaries 44
Aurobindo Pharma Ltd, Joint Venture 47

★海外企業調査レポート[Aurobindo Pharma Ltd (AUROPHARMA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Siam Cement Public Co Ltd:企業の戦略・SWOT・財務情報
    The Siam Cement Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Siam Cement Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • New York & Company, Inc.:企業の戦略・SWOT・財務情報
    New York & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary New York & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • CFF GmbH & Co KG :企業の戦略・SWOT・財務情報
    CFF GmbH & Co KG - Strategy, SWOT and Corporate Finance Report Summary CFF GmbH & Co KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Country Road Group Pty Ltd:企業の戦略的SWOT分析
    Country Road Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Calavo Growers, Inc. (CVGW):企業の財務・戦略的SWOT分析
    Calavo Growers, Inc. (CVGW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • ViaSat Inc:企業のM&A・事業提携・投資動向
    ViaSat Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ViaSat Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • SK Biopharmaceuticals Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Holdings Co Ltd is a developer of drug candidates. The company develops and markets innovative drugs for the treatment of central nervous system. It offers plumiaz, SKL-N05 and JZP-110; YKP3089, relenopride, SKL-PD, SKL …
  • Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析
    Summary Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbioti …
  • Advanced Metallurgical Group NV:企業の戦略・SWOT・財務情報
    Advanced Metallurgical Group NV - Strategy, SWOT and Corporate Finance Report Summary Advanced Metallurgical Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Simons Group Ltd:企業の戦略・SWOT・財務分析
    Simons Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Simons Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Ocular Therapeutix Inc (OCUL):企業の製品パイプライン分析2018
    Summary Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior …
  • i-Optics BV:医療機器:M&Aディール及び事業提携情報
    Summary I-Optics BV (I-Optics) is a medical device company that manufactures and distributes optical devices. The company offers Cassini, a corneal shape analyzer that measures the axis and magnitude of corneal astigmatism and EasyScan, a zero-dilation retinal imaging system to diagnose retinal dise …
  • Apartment Investment and Management Co:企業の戦略・SWOT・財務分析
    Apartment Investment and Management Co - Strategy, SWOT and Corporate Finance Report Summary Apartment Investment and Management Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • B. Braun Melsungen AG:企業の戦略・SWOT・財務分析
    B. Braun Melsungen AG - Strategy, SWOT and Corporate Finance Report Summary B. Braun Melsungen AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Obton AS:電力:M&Aディール及び事業提携情報
    Summary Obton A/S (Obton) is an investment company that offers management of assets within renewable energy. The company's investment process include screening process which inludes verification of prerequisites such as financial terms, amount of irradiation, power purchase agreement and feed-in tar …
  • The Clorox Company (CLX):企業の財務・戦略的SWOT分析
    The Clorox Company (CLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ISS AS:企業のM&A・事業提携・投資動向
    ISS AS - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ISS AS Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Evgen Pharma Plc (EVG):企業の財務・戦略的SWOT分析
    Summary Evgen Pharma Plc (Evgen Pharma), formerly Evgen Pharma Ltd is a clinical-stage drug development company. It is focused on the development of sulforaphane-based compounds for the treatment of cancer and neurological disease. Its pipeline product SFX-01 targets STAT3 signalling to inhibit stem …
  • Entreprise Tunisienne d’Activites Petrolieres:企業の戦略的SWOT分析
    Entreprise Tunisienne d'Activites Petrolieres - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Tonix Pharmaceuticals Holding Corp (TNXP):製薬・医療:M&Aディール及び事業提携情報
    Summary Tonix Pharmaceuticals Holding Corp (Tonix) is a developer of pharmaceutical products to address public health challenges. The company offers pharmaceutical products and treatments for disorders of the central nervous system including fibromyalgia, post traumatic stress disorder and episodic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆